References
- Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018;360:678.
- Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open. 2015;5(11):1–9.
- Lee C-C, Lee M-tG, Chen Y-S, et al. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Internal Med. 2015;175(11):1839–1847.
- Corps AN, Harrall RL, Curry VA, et al. Ciprofloxacin enhances the stimulation of matrix metalloproteinase 3 expression by interleukin-1β in human tendon-derived cells. Arthritis Rheumatol. 2002;46(11):3034–3040.
- Chang H-N, Pang J-HS, Chen CPC, et al. The effect of aging on migration, proliferation, and collagen expression of tenocytes in response to ciprofloxacin. J Orthop Res. 2012;30(5):764–768.
- Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. Quinolone and fluoroquinolone Article-31 referral. European Medicines Agency; 2019.
- European Association of Urololgy Guidelines. Urological infections 2020. [cited 2020 0204].
- Yang L, Gao L, Chen Y, et al. Prophylactic antibiotics in prostate biopsy: a meta-analysis based on randomized controlled trials. Surg Infect. 2015;16(6):733–747.
- Styrke J, Resare S, Lundström K, et al. Current routines for antibiotic prophylaxis prior to transrectal prostate biopsy: a national survey to all urology clinics in Sweden. F1000research. 2020;9:58.
- Van Hemelrijck M, Wigertz A, Sandin F, et al. Cohort Profile: the National Prostate Cancer register of sweden and prostate cancer data base sweden 2.0. Int J Epidemiol. 2013;42(4):956–967.
- Barlow L, KW, Holmberg L, et al. The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol. 2009;48(1):27–33. eng.
- Brooke HL, Talbäck M, Hörnblad J, et al. The Swedish cause of death register. Eur J Epidemiol. 2017;32(9):765–773.
- Wallerstedt SM, Wettermark B, Hoffmann M. The first decade with the Swedish prescribed drug register – a systematic review of the output in the scientific literature. Basic Clin Pharmacol Toxicol. 2016;119(5):464–469.
- Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.
- Statistics Sweden. Longitudinal integrated database for health insurance and labour market studies (LISA) 2019. [cited 2019 2019-12-13]. Available from: https://www.scb.se/en/services/guidance-for-researchers-and-universities/vilka-mikrodata-finns/longitudinella-register/longitudinal-integrated-database-for-health-insurance-and-labour-market-studies-lisa/
- Ekbom A. The Swedish multi-generation register. Methods Mol Biol. 2011;675:615–620.
- Hagel E, Garmo H, Bill-Axelson A, et al. PCBaSe Sweden: a register-based resource for prostate cancer research. Scand J Urol Nephrol. 2009;43(5):342–349.
- Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.
- James LM, Andrew JA, Robert RB, et al. Prostate cancer, version 1.2016. J Natl Compr Canc Netw. 2016;14(1):19–30.
- Nationellt Vårdprogram Prostatcancer. In: Centre RC, editor. 2020.
- Landenhed M, Engström G, Gottsäter A, et al. Risk profiles for aortic dissection and ruptured or surgically treated aneurysms: a prospective cohort study. J Am Heart Assoc. 2015;4(1):e001513.
- Carlsson S, Bratt O, Stattin P, et al. Current routines for transrectal ultrasound-guided prostate biopsy: a web-based survey by the Swedish Urology Network. Scand J Urol Nephrol. 2012;46(6):405–410.
- Bonkat G, Pilatz A, Wagenlehner F. Time to adapt our practice? the european commission has restricted the use of fluoroquinolones since march 2019. Eur Urol. 2019;76(3):273–275.
- Bonkat G, Wagenlehner F. In the line of fire: should urologists stop prescribing fluoroquinolones as default? Eur Urol. 2019;75(2):205–207.